Rigel Gains 77% in 3 Months: Is This an Indication to Buy the Stock?
RIGL shares surge 77% in three months as Tavalisse drives record sales along with other products while boosting the company's 2025 outlook.
Zacks·6d ago
More News
Can Tavalisse Drive Rigel's Growth Through the Rest of 2025?
RIGL's top line keeps growing on strong sales momentum for lead product, Tavalisse, while other products support growth.
Zacks·13d ago
What Makes Rigel Pharmaceuticals (RIGL) a Strong Momentum Stock: Buy Now?
Does Rigel Pharmaceuticals (RIGL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks·15d ago
Do Options Traders Know Something About RIGL Stock We Don't?
Investors need to pay close attention to Rigel Pharmaceuticals stock based on the movements in the options market lately.
Zacks·19d ago
Corcept Shares Rise 39.6% in YTD: How Should You Play the Stock?
CORT's stock is up 39.6% year to date as relacorilant nears FDA approval for Cushing's syndrome and expands into cancer studies.
Zacks·1mo ago
Rigel Pharmaceuticals, Inc. (RIGL) Soars to 52-Week High, Time to Cash Out?
Rigel (RIGL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks·1mo ago
Madrigal Gets Conditional Nod for MASH Drug Rezdiffra in EU
MDGL wins EU nod for Rezdiffra as the first and only approved MASH therapy. The drug's launch in Europe is expected in the fourth quarter of 2025.
Zacks·1mo ago
SNY's Rilzabrutinib Gets EU Orphan Drug Tag for IgG4-Related Disease
Sanofi wins EMA's orphan drug status for rilzabrutinib to treat IgG4-RD, a chronic, immune-mediated rare disease.
Zacks·1mo ago
Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run?
Xeris Biopharma (XERS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks·1mo ago
Earnings Estimates Moving Higher for Rigel (RIGL): Time to Buy?
Rigel Pharmaceuticals (RIGL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.